Johns Hopkins researchers helped secure full FDA approval to treat immunocompromised COVID-19 patients—paving the way to ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

Few of the many nonpharmacologic efforts to mitigate the spread of COVID-19 in nursing homes during the pandemic were evidence-based, and vaccinations and antiviral drugs were underused, concludes a ...

Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate ...

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...

Preliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction compared to Q3 2024 operating costs and expenses of $71.6 million Preliminary ending 2024 cash and ...

A data point is marked as “insufficient data” if wastewater samples test negative for a virus (because levels are too low to ...